| Cat. No. |
Product Name |
Information |
| PC-38814 |
Daxdilimab
Anti-ILT7 (CD85g, LILRA4) mAb
|
Daxdilimab (HZN-7734) is a fully human monoclonal antibody that binds to the ILT7 protein on the surface of plasmacytoid dendritic cells (pDCs) and recruits effector cells, such as natural killer (NK) cells, that help to kill pDCs. |
| PC-38813 |
Acapatamab
Anti PSMA/CD3 BiTE
|
Acapatamab (AMG 160) is a half-life extended anti-PSMA x anti-CD3 BiTE (bispecific T cell engager) antibody, is being investigated for the treatment of neuroendocrine prostate cancer. |
| PC-Ab1118 |
Camrelizumab
|
Camrelizumab (HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death protein 1 (PD-1), binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and p |
| PC-Ab1117 |
Girentuximab
|
Girentuximab (G250) is a monoclonal antibody (mAb) for targeting CA IX, a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). Carbonic anhydrase IX (CA IX) is the most widely expressed gene in response to hypoxia. Its crucial role in intracellular pH maintenance represents the means by which cancer cells adapt to the toxic conditions of the extracellular milieu.. |
| PC-Ab1116 |
Anti-mouse PD-1 (Mouse IgG1 D265A mutation)
|
Binds to PD-1, blocks PD-1 interaction with PD-L1 and PD-L2, Mouse IgG1 D265A mutation.. |
| PC-Ab1115 |
Sacituzumab
|
Sacituzumab is a human Trop-2 mAB that targets the Trop-2 protein and attaches to it. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.. |
| PC-Ab1114 |
Enfortumab
|
Nectin-4 is a tumour-associated antigen found on the surface of most urothelial carcinoma cells. In the antibody-drug conjugate enfortumab vedotin, human anti-nectin-4 antibody is linked to the cytotoxic microtubule-disrupting agent monomethyl auristatin E. Nectin-4 is both a new promising prognostic biomarker and specific therapeutic target for ADC in the very limited armamentarium against TNBC.. |
| PC-Ab1113 |
Moxetumomab
|
Moxetumomab pasudotox is an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. Moxetumomab binds to CD22 on HCL cells and leads to apoptotic cell death after internalization and trafficking of the toxin to the cytosol. CD22 is a single chain integral membrane molecule and a member of the immunoglobulin gene superfamily, an inhibitory B lymphocyte receptor specifically recognizing α2,6 sialic acids. It functions as an adhesion receptor and a signaling molec |
| PC-Ab1112 |
Polatuzumab
|
Polatuzumab (Anti-human CD79b) is a human CD79b mAb, component of antibody-drug conjugate (ADC) Polatuzumab vedotin. Polatuzumab is internalized, cleaved by lysosomal proteases, thereby delivering MMAE to malignant B-cells. The released MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis. CD79B is a subunit of the heterodimer B-cell receptor Igα/Igβ (CD79A/CD79B), also known as B29, Ig beta and B cell antigen receptor complex-associated protein |
| PC-Ab1111 |
KWAR23
|
KWAR23 is a monoclonal anti-human SIRPα antibody that binds to human SIRPα with high affinity, blocks the interaction of CD47 on one cell with SIRPα on a phagocytic cell. KWAR23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines, restores chemokine secretion in human macrophages in vitro, greatly augments myeloid cell-dependent killing of a collec-tion of hematopoietic and nonhematopoietic human tumor-derived cell lines.. |
| PC-Ab1110 |
Ofatumumab
|
Ofatumumab (GSK-1841157, OMB157) is a fully humanized, high-affinity monoclonal antibody whose epitope on CD20 is distinct from rituximab’s target. Ofatumumab induces efficient complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, even when CD20 expression is low. Ofatumumab inhibits early-stage B lymphocyte activation.. |
| PC-Ab1109 |
Guselkumab
|
Guselkumab (CNTO-1959) is a fully human immunoglobulin-G1-lambda (IgG1λ) monoclonal antibody, selectively binds to the p19 subunit of IL-23 in dendritic cells and keratinocytes and blocks its interaction with the IL-23 receptor, which further prevents the release of other pro-inflammatory cytokines and chemokines via stimulation of immune cells, such as T helper 17 (Th17) cells. Guselkumab serum levels of IL-17A, IL-17F, and IL-22, inhibits the release of proinflammatory cytokines and chemokines |
